ArticleJournal of cardiovascular pharmacology2026
Ceramide-Phospholipid Risk Score Associates With Cardiovascular Events and Is Lowered by Atorvastatin, Simvastatin, and Anti-PCSK9 Treatments.
Mika Hilvo et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.